CoChat
Sign Up
Cited by 159Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processesChronic Lymphocytic Leukemia Research

The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.

Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine

Open access
Pollyea, Daniel A., Pratz, Keith W., Wei, Andrew H., Pullarkat, Vinod, Jonas, Brian A., Recher, Christian, Babu, Sunil, Schuh, Andre C., Dail, Monique, Sun, Yan, Potluri, Jalaja, Chyla, Brenda, DiNardo, Courtney D.·2022·Clinical Cancer Research
DOI 10.1158/1078-0432.ccr-22-1183PMC PMC9751752

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Purpose: To evaluate efficacy and safety of venetoclax + azacitidine in treatment-naïve patients with acute myeloid leukemia harboring poor-risk cytogenetics and TP53mut or TP53wt. Patients and Methods: We analyzed data from a phase III study (NCT02993523) comparing venetoclax (400 mg orally days 1–28) + azacitidine (75 mg/m2 days 1–7) or placebo + azacitidine, and from a phase Ib study (NCT02203773) of venetoclax + azacitidine. Patients were ineligible for intensive therapy. TP53 status was analyzed centrally; cytogenetic studies were performed locally. Results: Patients (n = 127) with poor-risk cytogenetics receiving venetoclax + azacitidine (TP53wt = 50; TP53mut = 54) were compared with patients with poor-risk cytogenetics (n = 56) receiving azacitidine alone (TP53wt = 22; TP53mut = 18). For poor-risk cytogenetics + TP53wt patients, venetoclax + azacitidine versus azacitidine alone resulted in composite remission rates (CRc) of 70% versus 23%, median duration of remission (DoR) of 18.4 versus 8.5 months, and median overall survival (OS) of 23.4 versus 11.3 months, respectively. Outcomes with venetoclax + azacitidine were comparable with similarly treated patients with intermediate-risk cytogenetics and TP53wt. For poor-risk cytogenetics + TP53mut patients, venetoclax + azacitidine versus azacitidine alone resulted in CRc of 41% versus 17%, median DoR of 6.5 versus 6.7 months, and median OS of 5.2 versus 4.9 months, respectively. For poor-risk cytogenetics + TP53mut patients, predominant grade ≥3 adverse events (AE) for venetoclax + azacitidine versus azacitidine were febrile neutropenia (55%/39%), thrombocytopenia (28%/28%), neutropenia (26%/17%), anemia (13%/6%), and pneumonia (28%/33%). AEs were comparable between TP53mut and TP53wt patients. Conclusions: In poor-risk cytogenetics + TP53mut patients, venetoclax + azacitidine improved remission rates but not DoR or OS compared with azacitidine alone. However, in poor-risk cytogenetics + TP53wt patients, venetoclax + azacitidine resulted in higher remission rates and longer DoR and OS than azacitidine alone, with outcomes comparable with similarly treated patients with intermediate-risk cytogenetics. Toxicities were similar in TP53mut and TP53wt patients. See related commentary by Green and Zeidner, p. 5235

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-22-1183

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Azacitidine + venetoclax is standard of care for AML with CRc rate in mTP53 AML of 55% (CR ~20%) but without improvement of OS (<6 months).

    “Azacitidine (AZA) + venetoclax (VEN) is the standard of care for AML with a composite CR (CRc) rate in mTP53 AML of 55% (albeit CR rate of ~20%) but without improvement of OS (<6 months).”

    From Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML (2025) · cites this paper as [19]

    The Introduction (page unavailable) calls venetoclax plus azacitidine standard of care for treatment-naïve AML patients ineligible for intensive chemotherapy, not for all AML patients. The Results > Response to treatment (page unavailable) report a 40.7% CRc rate—not 55%—for patients with poor-risk cytogenetics and TP53-mutated AML; the copy does not establish the claimed approximately 20% CR rate. The Abstract > Results (page unavailable) reports median OS of 5.2 versus 4.9 months with combination therapy versus azacitidine alone, supporting the claim of no OS improvement in that subgroup. (LLM, conf=0.90)

    Experimental — accuracy not yet measured

  • AZA + VEN leads to CRc rate ~60%, true CR ~20%, with no improvement in median OS ~6 months in mTP53 AML across multiple studies.

    “AZA + VEN has emerged as the standard of care for all subtypes of AML in older and unfit patients, but the combination remains controversial in mTP53 AML because even though the combination leads to a CRc rate of approximately 60%, the true CR rate was ~20% with no improvement of the median OS of approximately 6 months observed across multiple studies”

    From Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML (2025) · cites this paper as [19]

    The Results (Response to treatment; page unavailable) report median overall survival of 5.2 months with venetoclax plus azacitidine versus 4.9 months with azacitidine alone in patients with poor-risk cytogenetics and TP53-mutated AML, supporting the claim of no survival improvement and roughly six-month survival. But the reported composite remission rate is 40.7%, not approximately 60%; the retrieved passages do not establish a roughly 20% CR rate or those figures across multiple studies. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

1 of the 29 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Related

Metadata

Authors
Pollyea, D. A., Pratz, K. W., Wei, A. H., Pullarkat, V., Jonas, B. A., Recher, C., Babu, S., Schuh, A. C., Dail, M., Sun, Y., Potluri, J., Chyla, B., & DiNardo, C. D.
Affiliations
  • University of Colorado Anschutz (US)
  • Abramson Cancer Center (US)
  • The Royal Melbourne Hospital (AU)
  • City Of Hope National Medical Center (US)
  • University of California Davis Medical Center (US)
  • 6Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
  • 7Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana.
  • Princess Margaret Cancer Centre (CA)
  • 9Genentech Inc., South San Francisco, California.
  • AbbVie (United States) (US)
  • The University of Texas MD Anderson Cancer Center (US)
Corresponding author
Pollyea, Daniel A.
ORCID
Venue
Clinical Cancer Research
Publisher
American Association for Cancer Research (AACR)
Published
2022-08-25
Volume
28
Issue
24
Pages
5272-5279
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
DOI
10.1158/1078-0432.ccr-22-1183
PMC
PMC9751752
OpenAlex
W4293253462
Cited by
159
References
29
Citations by year
2026: 24 · 2025: 41 · 2024: 44 · 2023: 39 · 2022: 10
FWCI
24.37
Type
journal article
Language
en
Open access
Licence
Locations
  • Clinical Cancer Research (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Digital Commons-TMC (Texas Medical Center) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by-nc-nd)
Funders
  • AbbVie (NCT02993523)
  • Genentech (NCT02203773)
Topics
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
Keywords
venetoclax, azacitidine, acute myeloid leukemia, poor-risk cytogenetics, TP53 mutation, wild-type p53, combination therapy, remission duration, overall survival, febrile neutropenia, adverse events, treatment-naive patients, elderly patients, prognostic factors, prognostic score
MeSH terms
Antineoplastic Combined Chemotherapy Protocols, Azacitidine, Humans, Mutation, Sulfonamides, Leukemia, Myeloid, Acute, Tumor Suppressor Protein p53, Treatment Outcome, Clinical Trials, Phase I as Topic, Clinical Trials, Phase III as Topic, Bridged Bicyclo Compounds, Heterocyclic, Cytogenetic Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review